Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine
Rhea-AI Summary
Psyence BioMed (Nasdaq: PBM) on April 17, 2026 acknowledged U.S. executive action preparations to evaluate ibogaine’s safety and therapeutic potential, while emphasizing its global leadership in GMP ibogaine manufacturing and an ethically sourced supply chain via PsyLabs.
Ibogaine remains a Schedule I substance in the U.S.; the company says controlled clinical research and standardized supply are essential to improve patient safety and enable regulated development.
AI-generated analysis. Not financial advice.
Positive
- GMP ibogaine manufacturing capability through PsyLabs
- Established ethically sourced ibogaine supply chain
Negative
- Ibogaine remains Schedule I in the United States
- Patients often seek access through unregulated settings outside the U.S.
News Market Reaction – PBM
On the day this news was published, PBM gained 29.47%, reflecting a significant positive market reaction. Argus tracked a peak move of +44.9% during that session. Our momentum scanner triggered 39 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $6.73M at that time.
Data tracked by StockTitan Argus on the day of publication.
Market Reality Check
Peers on Argus
PBM gained 103.82% with outsized volume, while momentum scanner only flags peer VRAX, which is down 5.21%. Other biotech peers in the list show modest single‑digit gains, supporting a PBM-specific reaction rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 08 | Clinical network expansion | Positive | -0.4% | Added two Australian sites to broaden Phase IIb trial footprint. |
| Mar 11 | Corporate platform update | Positive | -0.8% | Highlighted debt-free PsyLabs platform and first export milestone. |
| Mar 03 | Trial supply export | Positive | +3.5% | Exported GMP psilocybin NPX-5 to support Phase IIb trial in Australia. |
| Feb 20 | Equity investment structure | Neutral | -10.8% | Share-for-share investment following PsyLabs put option exercise. |
| Feb 17 | Shareholder meeting results | Negative | -9.7% | Approved potential share consolidations up to 250:1 and other matters. |
Operational and platform-building news has sometimes seen flat or negative reactions, while governance and capital-structure items have aligned with share price weakness.
Over the past six months, PBM has focused on building a vertically integrated psychedelics platform and advancing its Australian Phase IIb program. On Feb 17 and Apr 8, it expanded and supported clinical activities, yet shares moved modestly lower after those updates. A Feb 20 put-option equity investment and a Feb 12 shareholder meeting authorizing up to a 250:1 consolidation coincided with double‑digit percentage declines. Today’s policy-focused ibogaine news contrasts with these earlier, more company-specific milestones.
Market Pulse Summary
The stock surged +29.5% in the session following this news. A strong positive reaction aligns with PBM’s positioning around ibogaine, given the U.S. executive focus on evaluating this compound. The move to 5.87, up 103.82%, occurred with volume at 16.98x its recent average, suggesting heightened speculative interest. Historically, operational updates have not always held gains, so investors may watch how sentiment evolves once the policy impact and fundamentals are digested.
Key Terms
gmp technical
gmp-compliant technical
ptsd medical
AI-generated analysis. Not financial advice.
Company highlights global leadership in GMP ibogaine manufacturing and commitment to ethically sourced supply
NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a clinical-stage biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies, today acknowledged recent reports that the U.S. administration is preparing an executive order to further evaluate the safety and therapeutic potential of ibogaine, a naturally occurring compound being studied for its potential in treating post-traumatic stress disorder (PTSD), addiction, and other serious neurological and mental health conditions.
The anticipated executive action reflects growing recognition of the need for rigorous, regulated research into novel therapies, particularly in areas where current treatment options remain limited.
“Ibogaine has emerged as a compound of increasing global interest, particularly for its potential to address complex and treatment-resistant conditions,” said Jody Aufrichtig, Chief Executive Officer of Psyence BioMed. “We welcome efforts to advance structured, evidence-based research that can more clearly define its safety, efficacy, and role in clinical care.”
Ibogaine remains a Schedule I substance in the United States, and patients often seek access through unregulated settings outside the country. Psyence BioMed believes that advancing controlled clinical research and regulated development pathways is essential to improving both patient safety and long-term access.
Global Leadership in GMP Manufacturing and Ethical Sourcing
Through its strategic investment in PsyLabs, Psyence BioMed has established a leading position in the GMP-compliant manufacturing of ibogaine and ibogaine derivatives, with operations aligned to support global clinical research and future therapeutic development. The Company has also previously announced the development of a responsible and ethically sourced ibogaine supply chain, working within the compound’s native African ecosystem to ensure sustainability, traceability, and respect for traditional and environmental considerations.
As global interest in ibogaine accelerates, Psyence BioMed’s integrated platform – combining ethical sourcing, GMP manufacturing, and clinical development capabilities – positions the Company to play a meaningful role in supporting the next phase of research and potential regulatory evolution.
“Our focus has been on building a high-quality, ethically grounded supply chain that can support clinical research at scale,” added Aufrichtig. “As the regulatory environment evolves, the availability of standardized, responsibly sourced ibogaine will be critical to enabling credible scientific progress.”
About Psyence BioMed
Psyence Biomedical Ltd. (Nasdaq: PBM) is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics. It is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin and ibogaine-based psychedelic medicine to be listed on Nasdaq. We are dedicated to addressing unmet mental health needs. We are committed to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for a broad range of mental health disorders.
About PsyLabs
PsyLabs is a psychedelic Active Pharmaceutical Ingredient (API) development company, federally licensed to cultivate, extract, and export psilocybin mushrooms and other psychedelic compounds including psilocin, mescaline, ibogaine, and dimethyltryptamine (DMT) to legal medical and research markets. The company has successfully exported psilocybin products to Canada, the UK, Portugal, and Slovenia, and supplies purified extracts to its UK-based CMO partner.
PsyLabs operates from an ISO 22000 and GMP compliant facility, ensuring the highest standards of safety and traceability. With a focus on natural compound purification, regulatory support, and global distribution, PsyLabs is expanding its product pipeline to include ibogaine and other next-generation psychedelics.
www.psylabs.life
Learn more at www.psyencebiomed.com and on LinkedIn.
Contact Information for Psyence Biomedical Ltd.
Email: ir@psyencebiomed.com
Media Inquiries: media@psyencebiomed.com
General Information: info@psyencebiomed.com
Phone: +1 416-477-1708
Investor Contact:
Michael Kydd
Investor Relations Advisor
michael@psyencebiomed.com
Forward Looking Statements
This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations, and intentions with respect to future operations, products and services; and other statements identified by words such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “believe,” “intend,” “plan,” “projection,” “outlook” or words of similar meaning.
Forward-looking statements in this communication include statements regarding the progress of the Phase IIb clinical trial, and trial execution under the newly engaged CRO, and the creation of long-term shareholder value. These forward-looking statements are based on a number of assumptions, including the assumption that there will be no delays in the execution of the Phase IIb clinical trial implementation schedule, topline data from this trial will be positive, and that the demand for psychedelic-assisted therapy will continue to increase and that the Company will be able to maintain a share price trading above
These risks and uncertainties include, among others: (i) delays in the execution of the Phase IIb trial; (ii) the Company’s ability to maintain compliance with Nasdaq’s continued listing standards; (iii) volatility in the market price of the Company’s common stock due to a variety of factors, including the Company’s recent share consolidation, changes in market, economic or industry conditions in which Psyence BioMed operates and variations in performance across competitors, and (iv) changes in laws and regulations affecting Psyence BioMed’s business and changes in Psyence BioMed’s capital structure. Additionally, there can be no assurance that the anticipated executive order will be issued, or, if issued, that it will have any particular scope, timing or effect on the Company, its operations, product candidates or applicable regulatory pathways. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s final prospectus (File No. 333-284444) filed with the Securities and Exchange Commission (the “SEC”) on January 24, 2025 and other documents filed by Psyence BioMed from time to time with the SEC.
These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Actual results and future events could differ materially from those anticipated in such statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, Psyence BioMed does not intend to update these forward-looking statements.
The Company does not make any medical, treatment or health benefit claims about its proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, ibogaine, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by authorized clinical research. There is no assurance that the use of psilocybin, psilocybin analogues, ibogaine, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not conducted clinical trials for the use of the proposed products. Any references to quality, consistency, efficacy, and safety of potential products do not imply that the Company has verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.
